UNO A001
Alternative Names: UNO-A001Latest Information Update: 08 Jul 2024
At a glance
- Originator Tavotek Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 05 Apr 2024 Preclinical trials in Multiple myeloma in USA (Parenteral) prior to April 2024
- 05 Apr 2024 Pharmacodynamics and adverse events data from preclinical studies in Multiple myeloma presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Multiple myeloma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)